Last checked at 29 Jan 2021 10:19
IXICO plc
("IXICO" or the "Company")
PDMR Dealing
Issue of Equity on exercise of options
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 156,471 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options by the VP Alliance Management (PDMR).
The New Shares are expected to be admitted to trading on AIM on 5 February 2021.
Total voting rights
Application has been made for admission to trading on AIM of 156,471 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 5 February 2021, following which there will be in total 47,292,939 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.
The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
Details of PDMR transaction
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Sylke Grootoonk
| |||
2
| Reason for the notification
| ||||
a)
| Position/status
| PDMR (VP Alliance Management) | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| IXICO plc | |||
b)
| LEI
| 2138005M1F59O6HWSA97 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares in IXICO plc | |||
|
| ||||
Identification code | GB00BCLY7L40 | ||||
|
| ||||
b)
| Nature of the transaction
| Exercise of options | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Exercise Price(s) | Volume(s) |
| |
|
| 30.5p | 112,942 |
| |
|
| 34.0p | 43,529 |
| |
|
|
|
|
| |
d)
| Aggregated information |
| |||
|
| ||||
- Aggregated volume | 156,471 shares | ||||
|
| ||||
- Price | 31.5p | ||||
|
| ||||
e)
| Date of the transaction
| 5 Feburary 2021 | |||
f)
| Place of the transaction
| N/A | |||
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| |||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
|
| |||
Walbrook PR Ltd | +44 (0)20 7933 8780 | |||
Paul McManus / Lianne Cawthorne / | IXICO@walbrookpr.com | |||
Alice Woodings
|
| |||
|
|
|
|
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc